Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug
As per the agreement, Pfizer will invest $350m in Arvinas, representing about 7% of the stake.
Oncology
Wugen raises $172m to develop promising off-the-shelf NK cell therapies
Natural killer (NK) cell therapies in the T-cell acute lymphoblastic leukaemia (T-ALL) space have the...
China approves AstraZeneca’s Imfinzi for small-cell lung cancer
The approval is based on data from the Phase III CASPIAN trial, where the Chinese...
The competitive landscape of neoantigen-targeting therapeutics in oncology
New approaches to neoantigen therapy aim to predict the most important tumour antigens and formulate...
Sleeper cells: new stem cell state could put brain tumours to sleep
Arizona State University researchers have discovered a new resting phase of stem cells that could...
Sanofi to license multiple myeloma target domain from Eureka and MSK
Eureka and MSK will receive an undisclosed sum as upfront payment, as well as about $1bn in potential milestone payments.
AbbVie to acquire TeneoOne from Teneobio
The acquisition is an option exercise covered by a strategic partnership between AbbVie and TeneoOne.
Dante Labs acquires CCG.ai to build precision oncology software
The integrated platform would combine medical, germline, somatic and liquid biopsy data analysis for targeted cancer treatments.
Eisai and BMS partner to develop antibody drug conjugate for cancer
Eisai will get $650m from BMS and is also eligible for nearly $2.45bn in potential milestone payments.
Debiopharm and Ubix join forces to develop new anti-cancer modality
The companies are combining their proprietary technologies to develop Antibody Degraducer Conjugates.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
